lung cancer Non small cell lung cancer
Conditions
Interventions
A treatment plan is generated with a prescription dose of 3x18 Gy. The MLD will
be calculated in Normalized Total Dose (NTD) using the Linear
Quadratic(LQ)-model. If the calculated MLD falls in a ri
Sponsors
Antoni van Leeuwenhoek Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for riskgroup A and B - Weight loss 5 cm with tumor staging cT2bN0M0 or cT3N0M0 (chest wall infiltration is no exclusion criteria, as long as the tumor diameter is > 5 cm). - In patients without cytological or histological confirmation of NSCLC, a growing FDG-PET positive lesion (SUV >5) is accepted if a contra-indication for invasive diagnostic examination (or refusal) is present - Or a single peripheral lung metastasis in inoperable patients with a diameter of > 5 cm. In case of first presentation of metastatic disease, cytological or histological proof is obligated. Risk group B specification (lung metastases): - Patients with 2 peripheral lprimary NSCLC = 2 peripheral lung metastases
Exclusion criteria
Exclusion criteria: - patients with more lung tumors/metastases who will very likely be retreated within 6 months - Patients with central tumors - Pancoast tumors - Prior radiotherapy treatment to the thorax. - Patients previously treated with adriamycin agents in case of heart involvement within the treatment field - FEV1 and DLCO less than 40 % of the age-adjusted normal value - patients receiving any systemic treatment - pregnancy - patients receiving Bevacizumab within 3 months prior to SBRT or within 1 month post SBRT.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objective: The MLD that is associated with a 20% chance on dose limiting toxicity with a confidence interval of 10%. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives: - local control - regional control - overall survival - quality of life | — |
Countries
Netherlands
Outcome results
None listed